{"id":89409,"date":"2026-05-16T22:42:55","date_gmt":"2026-05-16T17:12:55","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=89409"},"modified":"2026-05-16T22:42:56","modified_gmt":"2026-05-16T17:12:56","slug":"zydus-lifesciences-analyst-review-2026","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-analyst-review-2026\/","title":{"rendered":"Zydus Lifesciences Analyst Review May 2026"},"content":{"rendered":"<p>This <strong>Zydus Lifesciences analyst review<\/strong> for May 2026 covers the key data investors need for ZYDUSLIFE at its current price of Rs 900. Zydus Lifesciences (NSE: ZYDUSLIFE) is a leading Indian pharmaceutical company with a market capitalisation of approximately Rs 91,000 crore, with strong US generics filings and a novel drug discovery pipeline. The analyst consensus target of Rs 1,050 implies meaningful upside from current levels, and this article examines the technical levels, business performance, valuation, and key risks that will determine whether ZYDUSLIFE achieves that target through FY27.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Click Here &#8211; Get Free Investment Predictions<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-analyst-review-2026\/#Zydus_Lifesciences_Company_Snapshot_May_2026\" title=\"Zydus Lifesciences Company Snapshot May 2026\">Zydus Lifesciences Company Snapshot May 2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-analyst-review-2026\/#Analyst_Insight_in_This_Zydus_Lifesciences_Analyst_Review\" title=\"Analyst Insight in This Zydus Lifesciences Analyst Review\">Analyst Insight in This Zydus Lifesciences Analyst Review<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-analyst-review-2026\/#Technical_Analysis_in_This_Zydus_Lifesciences_Analyst_Review\" title=\"Technical Analysis in This Zydus Lifesciences Analyst Review\">Technical Analysis in This Zydus Lifesciences Analyst Review<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-analyst-review-2026\/#Key_Support_and_Resistance_Levels\" title=\"Key Support and Resistance Levels\">Key Support and Resistance Levels<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-analyst-review-2026\/#Business_Segment_Analysis\" title=\"Business Segment Analysis\">Business Segment Analysis<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-analyst-review-2026\/#US_Generics_400_Plus_ANDAs_Complex_Injectables\" title=\"US Generics (400 Plus ANDAs, Complex Injectables)\">US Generics (400 Plus ANDAs, Complex Injectables)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-analyst-review-2026\/#India_Branded_Formulations_Cadila_Pharma\" title=\"India Branded Formulations (Cadila Pharma)\">India Branded Formulations (Cadila Pharma)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-analyst-review-2026\/#Novel_Drugs_Saroglitazar_Desidustat_and_Biosimilars\" title=\"Novel Drugs (Saroglitazar, Desidustat) and Biosimilars\">Novel Drugs (Saroglitazar, Desidustat) and Biosimilars<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-analyst-review-2026\/#Valuation_in_This_Zydus_Lifesciences_Analyst_Review\" title=\"Valuation in This Zydus Lifesciences Analyst Review\">Valuation in This Zydus Lifesciences Analyst Review<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-analyst-review-2026\/#Trade_Outlook_for_Zydus_Lifesciences\" title=\"Trade Outlook for Zydus Lifesciences\">Trade Outlook for Zydus Lifesciences<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-analyst-review-2026\/#Key_Risks_for_Zydus_Lifesciences_in_FY27\" title=\"Key Risks for Zydus Lifesciences in FY27\">Key Risks for Zydus Lifesciences in FY27<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-analyst-review-2026\/#Conclusion_Zydus_Lifesciences_Analyst_Review_Verdict_for_2026\" title=\"Conclusion: Zydus Lifesciences Analyst Review Verdict for 2026\">Conclusion: Zydus Lifesciences Analyst Review Verdict for 2026<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-analyst-review-2026\/#Frequently_Asked_Questions_Zydus_Lifesciences_Analyst_Review_2026\" title=\"Frequently Asked Questions: Zydus Lifesciences Analyst Review 2026\">Frequently Asked Questions: Zydus Lifesciences Analyst Review 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-analyst-review-2026\/#What_is_the_analyst_target_for_Zydus_Lifesciences_in_2026\" title=\"What is the analyst target for Zydus Lifesciences in 2026?\">What is the analyst target for Zydus Lifesciences in 2026?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-analyst-review-2026\/#Is_Zydus_Lifesciences_a_good_investment_at_Rs_900\" title=\"Is Zydus Lifesciences a good investment at Rs 900?\">Is Zydus Lifesciences a good investment at Rs 900?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-analyst-review-2026\/#What_is_Zydus_Lifesciencess_52-week_high_and_low\" title=\"What is Zydus Lifesciences&#8217;s 52-week high and low?\">What is Zydus Lifesciences&#8217;s 52-week high and low?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-analyst-review-2026\/#What_are_the_key_risks_for_Zydus_Lifesciences\" title=\"What are the key risks for Zydus Lifesciences?\">What are the key risks for Zydus Lifesciences?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/zydus-lifesciences-analyst-review-2026\/#Where_can_I_get_live_data_and_analyst_targets_for_Zydus_Lifesciences\" title=\"Where can I get live data and analyst targets for Zydus Lifesciences?\">Where can I get live data and analyst targets for Zydus Lifesciences?<\/a><\/li><\/ul><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Zydus_Lifesciences_Company_Snapshot_May_2026\"><\/span><strong>Zydus Lifesciences Company Snapshot May 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Zydus&#8217;s novel drugs include Saroglitazar (NASH, metabolic disorders) and Desidustat (anaemia in CKD). The US generics business with 400 plus ANDAs and a strong peptide and complex injectables portfolio drives revenue growth. The table below summarises the key data referenced in this <strong>Zydus Lifesciences analyst review<\/strong>.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Parameter<\/th>\n<th>Value<\/th>\n<\/tr>\n<tr>\n<td>NSE Ticker<\/td>\n<td>ZYDUSLIFE<\/td>\n<\/tr>\n<tr>\n<td>Sector<\/td>\n<td>Pharmaceuticals<\/td>\n<\/tr>\n<tr>\n<td>CMP (May 2026)<\/td>\n<td>Rs 900<\/td>\n<\/tr>\n<tr>\n<td>52 Week High<\/td>\n<td>Rs 1,320<\/td>\n<\/tr>\n<tr>\n<td>52 Week Low<\/td>\n<td>Rs 800<\/td>\n<\/tr>\n<tr>\n<td>Market Cap<\/td>\n<td>Rs 91,000 Crore<\/td>\n<\/tr>\n<tr>\n<td>Trailing P\/E<\/td>\n<td>22.00x<\/td>\n<\/tr>\n<tr>\n<td>Analyst Consensus Target<\/td>\n<td>Rs 1,050<\/td>\n<\/tr>\n<tr>\n<td>Bull Case Target<\/td>\n<td>Rs 1,300<\/td>\n<\/tr>\n<tr>\n<td>Bear Case Target<\/td>\n<td>Rs 780<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Analyst_Insight_in_This_Zydus_Lifesciences_Analyst_Review\"><\/span><strong>Analyst Insight in This Zydus Lifesciences Analyst Review<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Senior Research Analyst <strong>Ankit Jaiswal<\/strong> flags Zydus Lifesciences as a stock to watch in May 2026. At Rs 900, Ankit Jaiswal notes that the key levels for ZYDUSLIFE include support in the Rs 816 to Rs 855 band and resistance near Rs 954. He suggests watching Zydus Lifesciences for a potential move toward the consensus target of Rs 1,050, contingent on Pharmaceuticals sector momentum and Nifty 50 direction. Ankit Jaiswal&#8217;s view is one input in this <strong>Zydus Lifesciences analyst review<\/strong> and does not constitute a trade recommendation.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Technical_Analysis_in_This_Zydus_Lifesciences_Analyst_Review\"><\/span><strong>Technical Analysis in This Zydus Lifesciences Analyst Review<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>At Rs 900, ZYDUSLIFE is trading within its 52-week band of Rs 800 to Rs 1,320. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.<\/p>\n<p>Near-term support is identified in the Rs 816 to Rs 855 band while resistance is seen in the Rs 954 to Rs 975 zone. A sustained move above Rs 954 could open the path toward the analyst consensus of Rs 1,050.<\/p>\n<p><a href=\"https:\/\/univest.in\/screeners\"><strong>Screen the best stocks on the Univest Screener.<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Support_and_Resistance_Levels\"><\/span><strong>Key Support and Resistance Levels<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul>\n<li><strong>Support Zone:<\/strong> Rs 816 to Rs 855 &#8211; investors tracking this <strong>Zydus Lifesciences analyst review<\/strong> should watch for a stabilisation or bounce in this range as a potential accumulation signal.<\/li>\n<li><strong>Resistance Zone:<\/strong> Rs 954 to Rs 975 &#8211; a sustained close above Rs 954 would be a positive breakout signal worth flagging.<\/li>\n<li><strong>Medium-Term Target:<\/strong> The analyst consensus of Rs 1,050 represents the base-case upside for this <strong>Zydus Lifesciences analyst review<\/strong>.<\/li>\n<\/ul>\n<h2><span class=\"ez-toc-section\" id=\"Business_Segment_Analysis\"><\/span><strong>Business Segment Analysis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"US_Generics_400_Plus_ANDAs_Complex_Injectables\"><\/span><strong>US Generics (400 Plus ANDAs, Complex Injectables)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This is the primary revenue and margin driver for Zydus Lifesciences, directly supporting the earnings trajectory toward the consensus target of Rs 1,050.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"India_Branded_Formulations_Cadila_Pharma\"><\/span><strong>India Branded Formulations (Cadila Pharma)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This segment adds scale and diversification to Zydus Lifesciences&#8217;s business model and is a meaningful EPS contributor through FY27 and FY28.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Novel_Drugs_Saroglitazar_Desidustat_and_Biosimilars\"><\/span><strong>Novel Drugs (Saroglitazar, Desidustat) and Biosimilars<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This represents the medium-term growth frontier for Zydus Lifesciences and a key re-rating catalyst for the stock over the next 12 to 24 months.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Valuation_in_This_Zydus_Lifesciences_Analyst_Review\"><\/span><strong>Valuation in This Zydus Lifesciences Analyst Review<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>At Rs 900, Zydus Lifesciences trades at a trailing P\/E of 22.00x. This <strong>Zydus Lifesciences analyst review<\/strong> presents three scenarios: a bull case of Rs 1,300 on strong earnings delivery, a base case of Rs 1,050 at consensus, and a bear case of Rs 780 if macro headwinds persist. Q1 FY27 results will be the first key validation point.<\/p>\n<table>\n<tbody>\n<tr>\n<th>Scenario<\/th>\n<th>Target Price<\/th>\n<th>Key Condition<\/th>\n<\/tr>\n<tr>\n<td>Bull Case<\/td>\n<td>Rs 1,300<\/td>\n<td>Strong earnings and sector tailwinds<\/td>\n<\/tr>\n<tr>\n<td>Base Case (Consensus)<\/td>\n<td>Rs 1,050<\/td>\n<td>Moderate growth, analyst consensus estimate<\/td>\n<\/tr>\n<tr>\n<td>Bear Case<\/td>\n<td>Rs 780<\/td>\n<td>Earnings miss or macro headwinds<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2><span class=\"ez-toc-section\" id=\"Trade_Outlook_for_Zydus_Lifesciences\"><\/span><strong>Trade Outlook for Zydus Lifesciences<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Based on the technical and fundamental analysis in this <strong>Zydus Lifesciences analyst review<\/strong>, investors might watch ZYDUSLIFE near the support zone of Rs 816 to Rs 855 for potential opportunities. A flag above Rs 954 could suggest improving momentum toward Rs 1,050. This article uses watch-and-flag language only and does not constitute a trade recommendation.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Key_Risks_for_Zydus_Lifesciences_in_FY27\"><\/span><strong>Key Risks for Zydus Lifesciences in FY27<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>A well-rounded <strong>Zydus Lifesciences analyst review<\/strong> must assess downside risks. Key risks for Zydus Lifesciences include a macro slowdown affecting Pharmaceuticals sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in ZYDUSLIFE.<\/p>\n<p>Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or the <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Univest Android App<\/a> to get daily stock recommendations and expert research.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Conclusion_Zydus_Lifesciences_Analyst_Review_Verdict_for_2026\"><\/span><strong>Conclusion: Zydus Lifesciences Analyst Review Verdict for 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>This <strong>Zydus Lifesciences analyst review<\/strong> concludes that at Rs 900, ZYDUSLIFE offers a defined risk-reward with a consensus target of Rs 1,050. The 52-week range of Rs 800 to Rs 1,320 provides context on the current entry point. Use this <strong>Zydus Lifesciences analyst review<\/strong> as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on ZYDUSLIFE.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_Zydus_Lifesciences_Analyst_Review_2026\"><\/span><strong>Frequently Asked Questions: Zydus Lifesciences Analyst Review 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"What_is_the_analyst_target_for_Zydus_Lifesciences_in_2026\"><\/span><strong>What is the analyst target for Zydus Lifesciences in 2026?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The analyst consensus target is Rs 1,050, with a bull case of Rs 1,300 and a bear case of Rs 780. Monitor Q1 FY27 earnings for confirmation.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Is_Zydus_Lifesciences_a_good_investment_at_Rs_900\"><\/span><strong>Is Zydus Lifesciences a good investment at Rs 900?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>At Rs 900 with a P\/E of 22.00x and a consensus target of Rs 1,050, this <strong>Zydus Lifesciences analyst review<\/strong> is constructive for medium to long-term investors in the Pharmaceuticals sector. Always consult a SEBI-registered advisor before investing.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_is_Zydus_Lifesciencess_52-week_high_and_low\"><\/span><strong>What is Zydus Lifesciences&#8217;s 52-week high and low?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>The 52-week high is Rs 1,320 and the 52-week low is Rs 800. At Rs 900, ZYDUSLIFE is positioned within this range as noted in this <strong>Zydus Lifesciences analyst review<\/strong>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"What_are_the_key_risks_for_Zydus_Lifesciences\"><\/span><strong>What are the key risks for Zydus Lifesciences?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals sector.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Where_can_I_get_live_data_and_analyst_targets_for_Zydus_Lifesciences\"><\/span><strong>Where can I get live data and analyst targets for Zydus Lifesciences?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Track Zydus Lifesciences&#8217;s live price and analyst targets on the Univest Screener alongside professional financial advice.<\/p>\n<p><em>Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Zydus Lifesciences analyst review 2026: CMP Rs 900, target Rs 1,050, PE 22.00x. Technical levels, business analysis, and Pharmaceuticals sector outlook. May 202<\/p>\n","protected":false},"author":28,"featured_media":89719,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802],"class_list":["post-89409","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1778951579:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["80"],"rank_math_title":["Zydus Lifesciences Analyst Review 2026: Key Insights"],"rank_math_description":["Zydus Lifesciences analyst review 2026: CMP Rs 900, target Rs 1,050, PE 22.00x. Technical levels, business analysis, and Pharmaceuticals sector outlook. May 2026"],"rank_math_focus_keyword":["Zydus Lifesciences Analyst Review"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_thumbnail_id":["89719"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["11851"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/05\/16224241\/Zydus-Lifesciences.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/89409","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=89409"}],"version-history":[{"count":2,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/89409\/revisions"}],"predecessor-version":[{"id":89720,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/89409\/revisions\/89720"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/89719"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=89409"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=89409"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=89409"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}